Second meeting of National Academies drug pricing committee was far-reaching discussion of several major themes, including PBM transparency, the political future for co-pay coupons and the next possible inflection point: the potential $1 million price tag for gene therapies.
The lack of transparency on prescription drug pricing and the “opacity” of the revenue flow generated by high list prices were major themes of the second open meeting of the National Academies of Sciences, Engineering and Medicine (NASEM) ad hoc committee on patient access to affordable drug therapies in Washington, DC on Dec. 13.
The 18-member committee was chartered by the National Academies (formerly known as the Institute of Medicine) and is working toward...
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
